Further analysis of ND CBF‐AML cases in ihCAMs‐AML cohort revealed that UAMOCS2 included seven patients with CBFβ::MYH11, all of whom achieved CR after one induction chemotherapy cycle, whereas UAMOCS3 included eight patients with RUNX1::RUNX1T1 fusions, none of whom achieved CR. This evidence concerns the gene RUNX1 and acute myeloid leukemia.